title: Expression of the costimulator molecules, CD80, CD86, CD28, and CD152 on lymphocytes from neonates and young children.
abstract: The expression of CD80, CD86, CD28, and CD152 were examined on peripheral blood lymphocytes from adults, neonates (cord blood lymphocytes) and young children (2-20 months of age). There was no difference in the expression of CD80 or CD86 between adult and neonatal B cells, either resting or activated. A higher percentage of resting T cells expressed CD28 in neonates and young children compared to adults. CD28 expression was similar on adult and neonatal T cells activated with PMA and ionomycin. However, CD28 was expressed at greater intensity on a higher percentage of neonatal T cells than adult T cells stimulated with CD3. CD152 expression was lower on neonatal T cells than adult T cells stimulated with PMA and ionomycin and undetectable on neonatal T cells stimulated with CD3. In contrast, intracellular CD152 was equivalent in adult and neonatal T cells stimulated with PMA and ionomycin, suggesting trafficking of CD152 to the cell surface may be differentially regulated in neonatal T cells. Since the T cell response is determined by the balance of signals received from CD28 and CD152, high levels of CD28 expression and lower surface expression of CD152 on neonatal T cells may represent specialisation to promote activation of neonatal T cells.
authors.affiliation: Child Health Research Institute, Women's and Children's Hospital, South Australia, Australia.
authors.forename: S R
authors.initials: SR
authors.lastname: Elliott
authors.forename: P J
authors.initials: PJ
authors.lastname: Macardle
authors.forename: D M
authors.initials: DM
authors.lastname: Roberton
authors.forename: H
authors.initials: H
authors.lastname: Zola
mesh_terms: D000069594:Abatacept; D000328:Adult; D015703:Antigens, CD / Q000097:blood*; D000943:Antigens, Differentiation / Q000097:blood*; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018122:B7-1 Antigen / Q000097:blood*; D051940:B7-2 Antigen; D018106:CD28 Antigens / Q000097:blood*; D017252:CD3 Complex / Q000494:pharmacology; D060908:CTLA-4 Antigen; D005312:Fetal Blood / Q000276:immunology; D006801:Humans; D018796:Immunoconjugates; D066298:In Vitro Techniques; D007223:Infant; D007231:Infant, Newborn; D015759:Ionomycin / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000187:drug effects / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000097:blood*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D018122:B7-1 Antigen; D051940:B7-2 Antigen; D018106:CD28 Antigens; D017252:CD3 Complex; C497964:CD86 protein, human; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D008562:Membrane Glycoproteins; D015759:Ionomycin; D000069594:Abatacept; D013755:Tetradecanoylphorbol Acetate